Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Bladder cancer presents significant recurrence and treatment challenges, necessitating novel therapeutic targets.
• Reduced expression of small heat shock protein 6 (HSPB6) in bladder cancer indicates its potential role in tumor development.

Purpose of the Study:

• To investigate the functional role of HSPB6 in bladder cancer.
• To elucidate the molecular mechanisms underlying HSPB6's action, including its interaction with signaling pathways.

Main Methods:

• Integrative approach combining bioinformatics, RNA sequencing, and cell-based assays.
• Analysis of HSPB6 expression levels in bladder cancer tissues.
• Functional assays to assess the impact of HSPB6 modulation on cancer cell proliferation, metastasis, and apoptosis.
• Investigation of the regulatory relationship between TCF7L1, HSPB6, and the PI3K/AKT/mTOR pathway.

Main Results:

• HSPB6 upregulation was found to significantly inhibit bladder cancer cell proliferation and metastasis.
• Increased HSPB6 expression promoted apoptosis in cancer cells.
• TCF7L1 was identified as a key regulator that upregulates HSPB6 expression.
• Upregulation of HSPB6 led to the suppression of the pro-cancerous PI3K/AKT/mTOR signaling pathway.

Conclusions:

• HSPB6 acts as a tumor suppressor in bladder cancer.
• TCF7L1-mediated HSPB6 upregulation represents a promising therapeutic avenue by inhibiting the PI3K/AKT/mTOR pathway.
• HSPB6 is a compelling therapeutic target for developing novel bladder cancer treatment strategies.